[Edaily MarketIn | Reporter So-young Park]
MIMETICS, a startup providing skincare and medical solutions through biomimetic technology, announced on the 18th that it has secured seed round investment from FuturePlay and Mashup Ventures. The investment amount was not disclosed.

Founded in 2019 as a student startup at Sungkyunkwan University, MIMETICS has enhanced its R&D capabilities over the past five years through collaboration with Professor Chang-hyun Bang of the Department of Chemical and Polymer Engineering and his research team, building a strong foundation of research data. To date, the company has completed four technology transfers from the university and filed over 30 domestic and international patents, advancing commercialization efforts.

MIMETICS identified that the microscopic three-dimensional dome structure of octopus suction cups generates physical negative pressure, enabling adhesion regardless of environmental or surface conditions. In particular, the team confirmed that this 3D dome structure maintains adhesion even in challenging environments such as water, silicone oil, and humid skin.

Based on this technology, the company developed a wearable patch. The patch enables deeper penetration—up to three times greater—of active ingredients such as hyaluronic acid and peptides, which are effective for skincare but have traditionally struggled to cross the stratum corneum and deliver results.

With this investment, MIMETICS plans to continue securing talent by recruiting designers and strategic planners to support both its ODM (Original Development Manufacturing) and OBM (Original Brand Manufacturing) businesses.

Hyung-gi Park, CEO of MIMETICS, stated, “Through our safe, nature-inspired skin adhesion technology, we can expand into various industries including cosmetics, medical devices, and pharmaceuticals. This year, under our own brand ForAdore, we will focus on Pore Science and launch a focused beauty program that effectively cares for skin via drug delivery, along with the PDC (Pore Door Controller™) product lineup.”

Mo Sang-hyun, Executive Director at FuturePlay and lead investor, commented, “MIMETICS’ core biomimetic technology not only demonstrates excellent drug delivery efficacy but also carries the brand value of nature. We believe it has the potential to reshape the beauty market.”

So-young Park | sozero@edaily.co.kr